Asset Monetization LianBio is moving toward wind-down with asset sales and potential disposition of remaining assets. This creates concrete opportunities to monetize intellectual property, product licenses, or collaboration rights for markets in China and broader Asia. Business development teams should map potential buyers or licensees with alignment to the portfolio and IP.

Asia Market Access LianBio’s mission to accelerate medicines in China and major Asian markets signals readiness for Asia-centric partnerships. Potential partners include local distributors, contract research organizations, contract manufacturers, and commercialization firms who can accelerate regulatory filings, development support, and market access.

Strategic Partnerships The voluntary delisting and strategic wind-down may attract strategic buyers or private equity interested in a portfolio or platform assets. Present the opportunity as a turnkey entry with regional footprint, existing collaborations, and a clear pathway for asset divestiture or licensing.

Licensing Pipeline Any remaining clinical programs could be pursued through licensing or co-development deals with milestones and royalties, appealing to partners seeking Asia access. Emphasize readiness for due diligence, clear IP ownership, and known regulatory status to reduce deal risk.

Regulatory Advisory LianBio’s regional experience can be leveraged to offer regulatory and market-access advisory services to Western biotechs entering Asia, potentially creating a new revenue stream while the company winds down.